Jansen T, Bruch-Gerharz D, Reifenberger J, Schulte K W
Hautklinik des Universitätsklinikums Düsseldorf.
Hautarzt. 2013 Apr;64(4):228, 230-1. doi: 10.1007/s00105-013-2557-6.
A 73-year-old man, in whom 26 years ago a malignant melanoma with cervical lymph node metastases of the right retroauricular region was diagnosed, developed BRAF V600E-negative distant metastases, which progressed during both monochemotherapy and polychemotherapy. Therefore he was started on ipilimumab in a dose of 3 mg/kg body weight four times in intervals of 3 weeks. Subsequently, there was an almost complete regression of distant metastases. In several phase III trials a significant survival benefit has been identified for patients treated with ipilimumab. The human monoclonal antibody has been approved since July 2011 as a second-line treatment in Germany and was incorporated in January 2013 into the new guidelines for the treatment of malignant melanoma. The CTLA-4 antibody is the first drug that can improve significantly survival in patients with metastatic melanoma. In advanced (unresectable or metastatic) melanoma, immunostimulatory treatment with ipilimumab represents a new therapeutic option.
一名73岁男性，26年前被诊断为右耳后区域恶性黑色素瘤伴颈部淋巴结转移，现出现BRAF V600E阴性远处转移，在单药化疗和多药化疗期间病情进展。因此，开始给他使用剂量为3mg/kg体重的伊匹单抗，每3周一次，共4次。随后，远处转移几乎完全消退。在几项III期试验中，已确定接受伊匹单抗治疗的患者有显著的生存获益。自2011年7月起，这种人源单克隆抗体在德国被批准作为二线治疗药物，并于2013年1月被纳入恶性黑色素瘤治疗新指南。CTLA-4抗体是第一种能显著提高转移性黑色素瘤患者生存率的药物。在晚期（不可切除或转移性）黑色素瘤中，用伊匹单抗进行免疫刺激治疗是一种新的治疗选择。
